The effect of co-administration of opicapone on the pharmacokinetics of levodopa
Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…IPX203 dose conversion from immediate-release carbidopa-levodopa, in Parkinson’s disease patients with motor fluctuations.
Objective: To analyze dosing regimen data from a Phase 3 study in order to identify an optimal dose conversion from IR CD-LD to IPX203 for…Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study
Objective: To evaluate the effect of istradefylline (IST), an adenosine A2A receptor antagonist, on the adjustment of levodopa dose escalation in patients with Parkinson’s disease…Levodopa–entacapone–carbidopa intestinal gel infusion for advanced Parkinson’s disease patients – data from a Romanian center
Objective: To report the experience with levodopa–entacapone–carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease (PD) from a Romanian center. Background: LECIG…Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa
Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…Assessment of microstructural changes associated with levodopa-induced dyskinesia in hemiparkinsonian rodents
Objective: To assess white matter (WM) microstructural integrity changes in pre-clinical models of Parkinson’s disease (PD) with levodopa-induced dyskinesia (LID). Background: PD is a neurodegenerative…Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.
Objective: To analyze the relationship between nutritional intake and weight aspects in 3 groups of patients with Parkinson's disease (PD) who are receiving different pharmacological…Use of a wearable medical device for LCIG tube adjustment: a user case
Objective: To identify objectively the change in motor symptoms in a patient with Parkinson’s Disease (PD) on levodopa-carbidopa intestinal gel (LCIG) treatment with and without…Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials
Objective: To evaluate the effect of foslevodopa/foscarbidopa (LDP/CDP, ABBV-951) on clinical and patient-reported outcomes in advanced Parkinson’s disease (aPD) patients using minimal clinically important difference…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 62
- Next Page »